← Back to Screener
IN8bio, Inc. Common Stock (INAB)
Price$1.45
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-34.69%
Price vs S&P 500 (4W)-8.22%
VGM Score24.12
Market Capitalization$14.28M
All Metrics
Book Value / Share (Quarterly)$2.31
P/TBV (Annual)1.03x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.48
Price vs S&P 500 (YTD)-46.19%
EPS (TTM)$-3.04
10-Day Avg Trading Volume0.08M
EPS Excl Extra (TTM)$-3.04
EPS (Annual)$-4.44
ROI (Annual)-69.79%
Cash / Share (Quarterly)$2.23
ROA (Last FY)-60.22%
EBITD / Share (TTM)$-2.03
ROE (5Y Avg)-112.99%
Cash Flow / Share (Annual)$-1.30
P/B Ratio0.63x
P/B Ratio (Quarterly)0.64x
Net Income / Employee (Annual)$-1,143,500
Net Interest Coverage (TTM)-207.00x
ROA (TTM)-80.18%
EPS Incl Extra (Annual)$-4.44
Current Ratio (Annual)8.82x
Quick Ratio (Quarterly)10.35x
3-Month Avg Trading Volume0.06M
52-Week Price Return-59.72%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.56
52-Week High$4.17
EPS Excl Extra (Annual)$-4.44
CapEx CAGR (5Y)-10.74%
26-Week Price Return-26.77%
Quick Ratio (Annual)8.65x
13-Week Price Return-16.67%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)10.50x
Enterprise Value$-7.47M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.77
3-Month Return Std Dev84.21%
Net Income / Employee (TTM)$-1,116,500
ROE (Last FY)-70.54%
EPS Basic Excl Extra (Annual)$-4.44
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-3.04
ROI (TTM)-94.68%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.93
Price vs S&P 500 (52W)-84.09%
Year-to-Date Return-38.03%
5-Day Price Return-16.18%
EPS Normalized (Annual)$-4.44
ROA (5Y Avg)-83.12%
Month-to-Date Return-22.46%
Cash Flow / Share (TTM)$-1.05
EBITD / Share (Annual)$-4.14
LT Debt / Equity (Annual)3.57x
ROI (5Y Avg)-107.35%
LT Debt / Equity (Quarterly)0.14x
EPS Basic Excl Extra (TTM)$-3.04
P/TBV (Quarterly)1.32x
P/B Ratio (Annual)0.39x
Book Value / Share (Annual)$2.82
Price vs S&P 500 (13W)-24.92%
Beta0.27x
Revenue / Share (TTM)$0.00
ROE (TTM)-96.39%
52-Week Low$1.17
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.26est. -0.70
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.10
4.10
4.10
4.10
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
INABIN8bio, Inc. Common Stock | — | — | D | $1.45 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
IN8bio Inc is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid and liquid tumors using allogeneic, autologous, and engineered cell approaches. Lead programs include INB-400 for glioblastoma and INB-100 for high-risk leukemias, with additional candidates in earlier development stages.